by Bone metastasis occurs when cancer spreads from the original tumor to the bones. It is a common complication of breast cancer, prostate cancer, lung cancer and other Bone Metastasis in Solid Tumors . Bone metastases lead to severe pain, fractures and disability for cancer patients. Current treatments for bone metastases include chemotherapy, radiation therapy, bone targeted therapies, surgery and supportive care. Bone targeted therapies such as denosumab and bisphosphonates are the standard of care for treating cancers that have spread to the bones. These drugs help reduce fractures, spinal cord compression and other skeletal related issues in patients.
The global Bone Metastasis in Solid Tumors Market size is valued at US$ 4.8 billion in 2024 and is expected to register a CAGR of 5.7% over the forecast period 2024-2032.
Key Takeaways
Key players:
Key players operating in the bone metastasis market are F. Hoffmann-La Roche Ltd, Bayer AG, Merck & Co., Inc., Pfizer Inc., Novartis AG, Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited and Amgen Inc.
Growing demand: The demand for bone metastasis therapies is expected to rise significantly during the forecast period. This is attributed to the increasing prevalence of cancers worldwide and growing geriatric population prone to developing advanced and metastatic cancers. According to Global Cancer Observatory, the number of new cancer cases diagnosed globally each year is projected to rise from 18.1 million in 2018 to 29.5 million by 2040.
Global expansion: Leading pharmaceutical companies are expanding their product portfolio and geographical footprint to tap growing markets. Manufacturers are collaborating with local partners, undertaking mergers and acquisitions and setting up production facilities in developing Asian and Latin American countries. Furthermore, increasing awareness about available treatment options and favourable reimbursement policies are supporting the adoption of advanced therapies.
Market Key Trends
Rising prevalence of cancer is a major trend fueling the demand for bone metastasis therapies. As per WHO, cancer burden has risen to 19.3 million new cases and 10.0 million cancer deaths in 2020. Improvements in cancer diagnostics and screening programs have enabled early detection of bone metastases. Also, the development of novel targeted therapies with improved outcomes is boosting the market growth.
Porter’s Analysis
Threat of new entrants: The bone metastasis in Bone Metastasis in Solid Tumors market requires extensive R&D investments to develop new treatment options and gain regulatory approvals, limiting the threat of new entrants.
Bargaining power of buyers: Individual patients have little bargaining power considering the life-threatening nature of the condition. However, pharmaceutical companies must negotiate pricing and reimbursements with healthcare payers.
Bargaining power of suppliers: Established pharmaceutical manufacturers developing cancer drugs wield significant power as suppliers in this market given the specialized products required for treatment.
Threat of new substitutes: New treatment alternatives including targeted therapies and bone-protecting agents pose threats of substitution based on better efficacy or fewer side effects.
Competitive rivalry: Major players compete on the basis of their product portfolios and pipelines. However, the focus remains on improving patient outcomes rather than purely competing on costs given the seriousness of the disease.
Geographical Regions
North America currently accounts for the largest share of the bone metastasis in Bone Metastasis in Solid Tumors market, driven by high healthcare expenditures and widespread availability of advanced treatment options.
The Asia Pacific region is poised to witness the fastest growth over the forecast period due to rising incidence of cancer, improving access to healthcare resources, and increasing focus of global pharmaceutical companies on expanding in emerging economies.
What Are The Key Data Covered In This Bone Metastasis in Solid Tumors Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Bone Metastasis in Solid Tumors ‘s growth between 2024 and 2031.
:- Accurate calculation of the size of the Bone Metastasis in Solid Tumors and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Bone Metastasis in Solid Tumors Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Bone Metastasis in Solid Tumors vendors
Writer, has a strong foothold in the market research industry. She specializes in writing well-researched
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
